A bifunctional derivative of the versatile acyclic chelator H4octapa, p-SCN-Bn-H4octapa, has been synthesized for the first time. The chelator was conjugated to the HER2/neu-targeting antibody trastuzumab and labeled in high radiochemical purity and specific activity with the radioisotopes (111)In and (177)Lu. The in vivo behavior of the resulting radioimmunoconjugates was investigated in mice bearing ovarian cancer xenografts and compared to analogous radioimmunoconjugates employing the ubiquitous chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). The H4octapa-trastuzumab conjugates displayed faster radiolabeling kinetics with more reproducible yields under milder conditions (15 min, RT, ~94-95%) than those based on DOTA-trastuzumab (60 min, 37 °C, ~50-88%). Further, antibody integrity was better preserved in the (111)In- and (177)Lu-octapa-trastuzumab constructs, with immunoreactive fractions of 0.99 for each compared to 0.93-0.95 for (111)In- and (177)Lu-DOTA-trastuzumab. These results translated to improved in vivo biodistribution profiles and SPECT imaging results for (111)In- and (177)Lu-octapa-trastuzumab compared to (111)In- and (177)Lu-DOTA-trastuzumab, with increased tumor uptake and higher tumor-to-tissue activity ratios.
A bifunctional derivative of the versatile acyclic chelator H4octapa, pan class="Chemical">p-SCN-Bn-H4octapa, has been synthesized for the first time. The chelator was conjugated to the HER2/neu-targeting antibody trastuzumab and labeled in high radiochemical purity and specific activity with the radioisotopes (111)In and (177)Lu. The in vivo behavior of the resulting radioimmunoconjugates was investigated in mice bearing ovarian cancer xenografts and compared to analogous radioimmunoconjugates employing the ubiquitous chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). The H4octapa-trastuzumab conjugates displayed faster radiolabeling kinetics with more reproducible yields under milder conditions (15 min, RT, ~94-95%) than those based on DOTA-trastuzumab (60 min, 37 °C, ~50-88%). Further, antibody integrity was better preserved in the (111)In- and (177)Lu-octapa-trastuzumab constructs, with immunoreactive fractions of 0.99 for each compared to 0.93-0.95 for (111)In- and (177)Lu-DOTA-trastuzumab. These results translated to improved in vivo biodistribution profiles and SPECT imaging results for (111)In- and (177)Lu-octapa-trastuzumab compared to (111)In- and (177)Lu-DOTA-trastuzumab, with increased tumor uptake and higher tumor-to-tissue activity ratios.
Authors: Eric W Price; Jacqueline F Cawthray; Gwendolyn A Bailey; Cara L Ferreira; Eszter Boros; Michael J Adam; Chris Orvig Journal: J Am Chem Soc Date: 2012-05-11 Impact factor: 15.419
Authors: Jason P Holland; Vadim Divilov; Neil H Bander; Peter M Smith-Jones; Steven M Larson; Jason S Lewis Journal: J Nucl Med Date: 2010-07-21 Impact factor: 10.057
Authors: Raquel Ferreirós-Martínez; David Esteban-Gómez; Carlos Platas-Iglesias; Andrés de Blas; Teresa Rodríguez-Blas Journal: Dalton Trans Date: 2008-09-09 Impact factor: 4.390
Authors: Eric W Price; Kimberly J Edwards; Kathryn E Carnazza; Sean D Carlin; Brian M Zeglis; Michael J Adam; Chris Orvig; Jason S Lewis Journal: Nucl Med Biol Date: 2016-06-28 Impact factor: 2.408
Authors: Kevin P Labadie; Donald K Hamlin; Aimee Kenoyer; Sara K Daniel; Alan F Utria; Andrew D Ludwig; Heidi L Kenerson; Lily Li; Jonathan G Sham; Delphine L Chen; Johnnie J Orozco; Raymond S Yeung; Chris Orvig; Yawen Li; D Scott Wilbur; James O Park Journal: J Nucl Med Date: 2021-11-12 Impact factor: 11.082
Authors: Aohan Hu; Ivan Keresztes; Samantha N MacMillan; Yang Yang; Erdong Ding; Warren R Zipfel; Robert A DiStasio; John W Babich; Justin J Wilson Journal: Inorg Chem Date: 2020-03-27 Impact factor: 5.165
Authors: Sai Kiran Sharma; Jonathan M Glaser; Kimberly J Edwards; Elaheh Khozeimeh Sarbisheh; Akam K Salih; Jason S Lewis; Eric W Price Journal: Bioconjug Chem Date: 2020-04-01 Impact factor: 6.069